Search
Ecabet
go.drugbank.com/drugs/DB05265InvestigationalEcabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis. … Ecabet is a prescription eye drop for the treatment of dry eye syndrome.
Categories: Compounds used in a research, industrial, or household setting, Pepsin A, antagonists & inhibitorsAmoxapine
go.drugbank.com/drugs/DB00543ApprovedIn depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation.
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexTiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … [A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.
Categories: Phospholipases A, antagonists & inhibitorsGenistein
go.drugbank.com/drugs/DB01645InvestigationalIt has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms. … Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties.
Categories: Compounds used in a research, industrial, or household settingMirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigational[L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023. … Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.
Teprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigational[L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was … multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis. … Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric … Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital
Ingenol mebutate
go.drugbank.com/drugs/DB05013ApprovedWithdrawnPEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions … Before approval, ingenol mebutate was called PEP005 as an investigational drug.
Hetacillin
go.drugbank.com/drugs/DB00739ApprovedVet approvedWithdrawnHetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. … Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria.